AddLife acquires BonsaiLab
AddLife acquires BonsaiLab, a leading Spanish distributor in the field of cell and molecular biology. The company, with current revenues of EUR 8 m, has operations in Spain and Portugal and will be included in AddLife’s business area Labtech.
BonsaiLab is a biotech company providing a portfolio of market-leading instruments and consumables in the field of cell and molecular biology. The company’s offering includes cutting-edge technology products, analytical solutions, and services for genomics laboratories in Spain and Portugal, including products for next generation sequencing, genomic analysis as well as sample preparation.
BonsaiLab is a fast-growing company with strong margins and revenues of some EUR 8 m. The company has 13 employees and is headquartered in Alcobendas, just outside Madrid.
BonsaiLab will be included in the Biomedical and Research business unit, a part of the Labtech business area.
“The acquisition expands our presence in the prioritized and fast-growing market segment molecular biology, in which we are already well-established in the Nordic region and several other countries. BonsaiLab is a great strategic fit for AddLife. The acquisition will enhance our market position in Europe and further strengthen our long-term business relationships with key suppliers. I am excited to welcome the BonsaiLab team to the AddLife family.”, says Mattias Bengtsson, Business Unit Manager, Biomedical and Research, AddLife.
”I am very excited about the new opportunities, and relevant experience, that AddLife will bring to BonsaiLab. The move will enable further expansion on the Iberian market and being part of the larger AddLife Group with a broad European presence is an exciting development for our employees, our suppliers, and our customers. I look forward to leading BonsaiLab into the next chapter of our journey as we continue to develop and grow.” says Rafael Calderón, CEO and major shareholder of BonsaiLab
The closing took place on July 4, 2024. The acquisition is expected to have a slight positive impact on AddLife’s earnings per share during the current financial year.
Stockholm, July 5, 2024
AddLife AB (publ)
For more information, contact;
Fredrik Dalborg, President and CEO, fredrik.dalborg@add.life, +46 70 516 09 01
Christina Rubenhag, CFO, christina.rubenhag@add.life +46 70 546 72 22
AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors, mainly in the Nordic region and rest of Europe. AddLife has about 2,300 employees in some 85 operating subsidiaries. The Group currently has net sales of approximately SEK 10 billion. AddLife shares are listed on Nasdaq Stockholm.
The information was submitted for publication on July 5, 2024 at 07:45 a.m. CET.